Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRIDGEWATER, N.J., AUG. 14, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY REPORTED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED JUNE 30, 2025.

VYNE THERAPEUTICS REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

TRIAL DID NOT MEET PRIMARY ENDPOINT OR KEY SECONDARY ENDPOINT OF F-VASI50 AND F-VASI75 NOMINALLY STATISTICALLY SIGNIFICANT EFFECTS OBSERVED IN KEY SECONDARY AND EXPLORATORY ENDPOINTS OF CHANGE FROM BASELINE IN F-VASI AND T-VASI AT 3% CONCENTRATION COMPANY WILL TERMINATE EXTENSION PHASE OF TRIAL AND SEEK EXTERNAL PARTNER FOR CONTINUED DEVELOPMENT OF REPIBRESIB BRIDGEWATER, N.J., JULY 30, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED TOPLINE RESULTS FROM ITS PHASE 2B TRIAL EVALUATING REPIBRESIB GEL IN NONSEGMENTAL VITILIGO.

VYNE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B TRIAL WITH REPIBRESIB GEL IN NONSEGMENTAL VITILIGO

BRIDGEWATER, N.J., JULY 02, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY PROVIDED A PROGRAM UPDATE FOR VYN202 FOLLOWING THE CLINICAL HOLD ISSUED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN APRIL FOR THE COMPANY'S PHASE 1B CLINICAL TRIAL IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS. VYN202 IS AN ORAL SMALL MOLECULE BD2-SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITOR THAT IS BEING DEVELOPED FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES.

VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202

REPIBRESIB GEL (VYN201) PHASE 2B VITILIGO TOP-LINE RESULTS EXPECTED IN MID-2025 EXPECTED CASH RUNWAY INTO 2H 2026 BRIDGEWATER, N.J., MAY 08, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED FINANCIAL RESULTS AS OF AND FOR THE QUARTER ENDED MARCH31, 2025, AND PROVIDED A BUSINESS UPDATE.

VYNE THERAPEUTICS REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., APRIL 25, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) VERBALLY INFORMED THE COMPANY THAT IT PLACED A CLINICAL HOLD ON THE COMPANY'S PHASE 1B STUDY EVALUATING VYN202 FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS. THE CLINICAL HOLD DETERMINATION WAS MADE FOLLOWING A RECENT OBSERVATION OF TESTICULAR TOXICITY IN DOGS FROM A NON-CLINICAL TOXICOLOGY STUDY WITH VYN202.

VYNE THERAPEUTICS PROVIDES UPDATE ON VYN202 PROGRAM

BRIDGEWATER, N.J., MARCH 20, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED THAT VYNE'S MANAGEMENT WILL PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL AUTOIMMUNE & INFLAMMATORY DISEASE VIRTUAL CONFERENCE (SKIN DISEASES, CONDITIONS AND DISORDERS) BEING HELD ON THURSDAY, MARCH 27, 2025.

VYNE THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT3RD ANNUAL AUTOIMMUNE & INFLAMMATORY DISEASE VIRTUAL CONFERENCE

REPIBRESIB GEL (VYN201) PHASE 2B VITILIGO TOP-LINE RESULTS EXPECTED IN MID-2025 VYN202 PHASE 1B PSORIASIS TRIAL INITIATED WITH RESULTS ANTICIPATED BY YEAR-END 2025 EXPECTED CASH RUNWAY INTO 2H 2026 BRIDGEWATER, N.J., MARCH 06, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED FINANCIAL RESULTS AS OF AND FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER31, 2024, AND PROVIDED A BUSINESS UPDATE.

VYNE THERAPEUTICS REPORTS 2024 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., FEB. 20, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED THAT VYNE'S MANAGEMENT WILL PARTICIPATE IN TWO INVESTOR CONFERENCES IN MARCH.

VYNE THERAPEUTICS TO PARTICIPATE IN MARCH INVESTOR CONFERENCES

BRIDGEWATER, N.J., FEB. 19, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED THAT THE FIRST SUBJECT HAS BEEN DOSED IN A PHASE 1B TRIAL EVALUATING VYN202 IN MODERATE-TO-SEVERE PLAQUE PSORIASIS. VYN202 IS AN ORAL SMALL MOLECULE BD2-SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITOR THAT IS BEING DEVELOPED FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES. THE PHASE 1B TRIAL WILL PRIMARILY EVALUATE THE SAFETY OF VYN202, ADMINISTERED ORALLY ONCE A DAY FOR 12 WEEKS, WITH SECONDARY OBJECTIVES TO EVALUATE THE PHARMACOKINETIC PROFILE AND PRELIMINARY EVIDENCE OF EFFICACY, INCLUDING IMPROVEMENT FROM BASELINE IN PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORES. TOP-LINE DATA FROM THE 12-WEEK RANDOMIZED, PLACEBO-CONTROLLED TRIAL ARE EXPECTED BY YEAR-END 2025.

VYNE THERAPEUTICS INITIATES PHASE 1B TRIAL OF VYN202, A NOVEL BD2-SELECTIVE ORAL BET INHIBITOR, IN PLAQUE PSORIASIS

BRIDGEWATER, N.J., JAN. 06, 2025 (GLOBE NEWSWIRE) -- VYNE THERAPEUTICS INC. (NASDAQ: VYNE) (VYNE OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING DIFFERENTIATED THERAPIES TO TREAT CHRONIC INFLAMMATORY AND IMMUNE-MEDIATED CONDITIONS WITH HIGH UNMET NEED, TODAY ANNOUNCED COMPLETION OF ENROLLMENT IN THE PHASE 2B TRIAL EVALUATING VYN201 GEL FOR THE TREATMENT OF NONSEGMENTAL VITILIGO. TOP-LINE DATA FROM THE 24-WEEK VEHICLE-CONTROLLED TREATMENT PERIOD ARE EXPECTED IN MID-2025.

VYNE Therapeutics Inc.

VYNE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VYNE Therapeutics Inc.

VYNE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VYNE